Stuttgart - Delayed Quote EUR

Corcept Therapeutics Inc (HTD.SG)

60.20

-1.56

(-2.53%)

As of 8:01:25 AM GMT+2. Market Open.

Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic over […]

Insider Monkey 16 hours ago

CORT
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

REDWOOD CITY, Calif., April 23, 2025--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASCO)

Business Wire 17 hours ago

CORT
Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

REDWOOD CITY, Calif., April 21, 2025--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the publication of findings from the prevalence phase of the CATALYST trial in Diabetes Care, a peer-reviewed journal published by the American Diabetes Association.

Business Wire 2 days ago

CORT
Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter

Corcept Therapeutics (NasdaqCM:CORT) saw a remarkable 36% increase in its share price in the last quarter, driven by several key developments. The company's significant announcement on March 31, detailing the successful Phase 3 trial results of the ROSELLA study, likely provided a strong boost to investor confidence, as it highlighted a 30% reduction in disease progression risk for its treatment in ovarian cancer. This positive momentum was further supported by the initiation of the BELLA and...

Simply Wall St. 14 days ago

CORT
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif., April 07, 2025--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in patients with platinum-resistant ovarian cancer.

Business Wire 16 days ago

CORT
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

CORT and AXSM are in the spotlight this week following the announcement of study data.

Zacks 21 days ago

CORT

EXEL
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 21 days ago

CORT
Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz

The major averages were mostly lower near noon, with the Dow up fractionally but the Nasdaq down nearly 250 points amid mounting concerns about President Donald Trump’s upcoming announcement of promised new tariffs. Meanwhile, the S&P 500’s early losses brought the index to its lowest level since September. Looking to commodities, gold prices are sharply higher, continuing their rally to over $3,150, while oil prices are also up over 2.5%. Get caught up quickly on the top news and calls moving s

TipRanks 22 days ago

GT

MU

HUT
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian cancer meets the primary endpoint.

Zacks 22 days ago

CORT
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?

Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 22 days ago

CORT

IRWD
Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday?

We recently published a list of 10 Firms Kick Off Trading Week Stronger. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other firms that kicked off the trading week stronger. The stock market began the trading week on a mixed note as investors continued to […]

Insider Monkey 22 days ago

CORT

^GSPC
Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement

The trial outcomes are said to support a new drug application in the US and a European marketing authorisation application.

Clinical Trials Arena 22 days ago

CORT
Equity Markets Mixed Ahead of Tariff Announcements

US benchmark equity indexes are on track to close mixed on Monday, as markets get ready for more tar

PREMIUM
MT Newswires 23 days ago

^GSPC

COMP

^DJI
Why Is Corcept (CORT) Stock Soaring Today

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving progression-free survival and overall survival in treating resistant ovarian cancer with a new therapy (a combination of Relacorilant and Nab-paclitaxel).

StockStory 23 days ago

CORT
Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip

Corcept Therapeutics (NasdaqCM:CORT) recently announced successful results from its ROSELLA trial for relacorilant plus nab-paclitaxel, indicating a notable positive stride in treatment for platinum-resistant ovarian cancer. This announcement, emphasizing a significant improvement in progression-free and overall survival, aligns with the company’s 8% share price uptick over the last quarter. Despite broader market challenges and a slide in major indices like the S&P 500 and Nasdaq, Corcept’s...

Simply Wall St. 23 days ago

CORT
NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute

Josh Lipton takes a closer look at the top stories on Wall Street on today's Market Minute: NewsMax (NMAX) stock skyrockets after going public, Celsius Holdings (CELH) pops on a Truist analyst upgrade, and Corcept Therapeutics (CORT) climbs on positive drug trial results.Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video 23 days ago

NMAX

CELH

CORT
Yum Brands, Corcept Therapeutics, Hut 8: Trending tickers

Here are some stocks on the move for Monday, March 31. Yum Brands (YUM) is searching for a new CEO as current head David Gibbs plans to retire in early 2026, after 36 years with the company. Corcept Therapeutics (CORT) shares are rising after a successful trial for its ovarian cancer drug. Shares of Hut 8 (HUT) are on the move after announcing a new venture with the Trump family to launch a bitcoin mining venture. To watch more expert insights and analysis on the latest market action, check out more Wealth here.

Yahoo Finance Video 23 days ago

YUM

CORT

HUT
Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump

Corcept Therapeutics (CORT) said Monday its phase 3 trial of relacorilant plus nab-paclitaxel to tre

PREMIUM
MT Newswires 23 days ago

CORT
Corcept's ovarian cancer drug cuts disease progression in study, shares jump

(Reuters) -Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial. The drug, relacorilant, in combination with chemotherapy, helped patients live a month longer without their disease worsening and reduced the risk of cancer progression by 30% in ovarian cancer patients who were resistant to platinum-based chemotherapy treatments, compared with those on chemotherapy alone, meeting one of the main goals of the study.

Reuters 23 days ago

CORT
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

REDWOOD CITY, Calif., March 31, 2025--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer, met its primary endpoint of improved progressi

Business Wire 23 days ago

CORT

Performance Overview

Return	HTD.SG	S&P 500 (^GSPC)
YTD	+21.22%	-8.60%
1-Year	+188.59%	+6.00%
3-Year	+190.12%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Corcept Therapeutics Inc (HTD.SG)

Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?

Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz

CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal

Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?

Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday?

Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement

Equity Markets Mixed Ahead of Tariff Announcements

Why Is Corcept (CORT) Stock Soaring Today

Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip

NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute

Yum Brands, Corcept Therapeutics, Hut 8: Trending tickers

Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump

Corcept's ovarian cancer drug cuts disease progression in study, shares jump

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Performance Overview